Reduction in late mortality among patients with Multiple Myeloma treated with Autologous Peripheral Blood Stem Cell Transplantation – a BMTSS Report

The past two decades have witnessed a sizeable improvement in survival among patients with Multiple Myeloma (MM).1 This is particularly true for younger patients ( ≤65y) where 10y survival rates now exceed 35%.2,3 With an increased lifespan, late complications of therapy and their contribution towards late mortality have become more relevant.

Source: Biology of Blood and Marrow Transplantation - June 18, 2021 Category: Hematology Authors: Smith Giri, Yanjun Chen, Jessica Wu, Lindsey Hageman, Joshua Richman, Liton Francisco, Wendy Landier, Luciano Costa, Andrew McDonald, Donna Murdaugh, F Lennie Wong, Daniel J. Weisdorf, Stephen J. Forman, Mukta Arora, Saro H. Armenian, Smita Bhatia Source Type: research